| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Sirolimus | FAERS: 3 | OFFSIDES US FAERS | |
| 2 | Dabigatran | FAERS: 1 | US FAERS | |
| 3 | Diclofenac | FAERS: 1 | US FAERS | |
| 4 | Everolimus | FAERS: 1 | US FAERS | |
| 5 | Fondaparinux | FAERS: 1 | US FAERS | |
| 6 | Octreotide | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 7 | Prednisolone | FAERS: 1 | US FAERS | |
| 8 | reviparin | FAERS: 1 | US FAERS | |
| 9 | Acetylcysteine | OFFSIDES | ||
| 10 | Ceftazidime | OFFSIDES | ||
| 11 | Clonidine | OFFSIDES | ||
| 12 | Dihydroergotamine | OFFSIDES | ||
| 13 | Erlotinib Hydrochloride | OFFSIDES | ||
| 14 | Loxapine | OFFSIDES | ||
| 15 | Prednisone acetate | OFFSIDES | ||
| 16 | Sitagliptin Phosphate | OFFSIDES | ||
| 17 | Sodium Bicarbonate | OFFSIDES | ||
| 18 | Trihexyphenidyl | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.